Objective: Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA).
Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in …

Objective Polymyalgia rheumatica (PMR) is often the presenting manifestation of giant cell
arteritis (GCA). Fluorine-18-fluorodeoxyglucose positron emission tomography/computed …

Giant cell arteritis (GCA) is the most common vasculitis in individuals older than 50 years in
Western countries. In addition to the typical pattern of cranial ischemic manifestations, large …

Early recognition of giant cell arteritis (GCA) is crucial to avoid the development of ischemic
vascular complications, such as blindness. The classic approach to making the diagnosis of …

Objective. Clinical improvement following tocilizumab (TCZ) therapy in patients with large-vessel
(LVV) giant cell arteritis (GCA) is well established. However, information on TCZ effect …

Objectives Clinical presentations of giant cell arteritis (GCA) are protean, and it is vital to
make a secure diagnosis and exclude mimics for urgent referrals with suspected GCA. The …

Giant cell arteritis (GCA) is the most common vasculitis among elderly people. The clinical
spectrum of the disease is heterogeneous, with a classic/cranial phenotype, and another …

Introduction: Early diagnosis of interstitial lung disease (ILD) associated with rheumatoid
arthritis (RA) constitutes a challenge for the clinicians. Pulmonary vasculopathy is relevant in …

Interstitial lung disease (ILD) may occur in patients with a rheumatic autoimmune disease (AD),
increasing their risk of morbidity and mortality. However, little is known about the …

In the present study, we aimed to report our experience with rituximab (RTX) in the treatment
of patients with ILD associated with AD (AD-ILD) at a single center. For this purpose, clinical …